A $60 million initiative launched today signals a critical course correction in the rush to deploy Artificial Intelligence in global health. The Evidence for AI in Health (EVAH) initiative, funded by the Gates Foundation, Novo Nordisk Foundation, and Wellcome, isn’t about *building* more AI tools; it’s about rigorously evaluating the ones already in development and determining their real-world impact in low- and middle-income countries (LMICs). This move acknowledges a growing concern that AI’s potential to revolutionize healthcare is being hampered by a lack of robust, locally-relevant evidence.
- $60 Million Investment: The EVAH initiative will fund locally-led evaluations of AI health tools in sub-Saharan Africa, South Asia, and Southeast Asia.
- Focus on Decision Support: The initial call for proposals prioritizes AI tools assisting frontline workers in primary and community health settings (triage, diagnosis, referral).
- Addressing an Evidence Gap: A recent Lancet study revealed that only 4 of 86 identified AI health trials globally between 2018-2023 were conducted in LMICs.
The urgency behind EVAH stems from a confluence of factors. The AI health space has exploded in recent years, fueled by advancements in machine learning and large language models. However, the vast majority of development and testing has occurred in high-income countries, with limited consideration for the unique challenges and contexts of LMICs – from data scarcity and infrastructure limitations to cultural acceptability and workforce capacity. The philanthropic community, having already invested heavily in AI development, is now recognizing the need to ensure these investments translate into tangible health improvements, rather than becoming costly failures.
This initiative builds on a broader $300 million partnership announced in 2024, demonstrating a sustained commitment to global health R&D. The selection of J-PAL and APHRC as implementation partners is particularly noteworthy. Both organizations have a strong track record of conducting rigorous impact evaluations and working collaboratively with local researchers, ensuring the initiative remains grounded in local needs and priorities. Nigeria’s Minister of Communications, Innovation, and Digital Economy, Dr. Bosun Tijani’s, statement underscores the importance of AI not just as a technological advancement, but as a driver of economic growth and sustainable development.
The Forward Look
EVAH represents a pivotal shift towards responsible AI implementation in global health. However, its success hinges on several key factors. First, the initiative must prioritize transparency and open access to data, ensuring that findings are widely disseminated and can inform policy decisions beyond the immediate scope of the funded evaluations. Second, the focus on “implementation science” – understanding *how* to effectively integrate AI tools into existing health systems – is crucial. Simply demonstrating efficacy in a controlled trial is insufficient; the tools must be feasible, affordable, and acceptable to both healthcare workers and patients.
Looking ahead, we can anticipate increased scrutiny of AI health interventions in LMICs. Funders will likely demand more robust evidence of impact *before* committing significant resources to scale-up. This could lead to a more competitive landscape for AI developers, favoring those who prioritize rigorous evaluation and local adaptation. Furthermore, the EVAH initiative could serve as a model for other sectors – such as agriculture and education – seeking to leverage AI for development, emphasizing the importance of evidence-based decision-making and locally-led innovation. The next 18-24 months will be critical as the first wave of evaluations gets underway, and the initial findings begin to shape the future of AI in global health.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
